Kaos Capital takes 4.9% stake in BioRestorative, pushes for AI pivot

Kaos Capital, an activist hedge fund based in Miami, has acquired a 4.9% stake in BioRestorative Therapies (NASDAQ:BRTX) and plans to push the biotechnology company to pivot toward artificial intelligence opportunities.

The investment firm accumulated the shares through a series of open-market purchases.

The transaction positions Kaos Capital just below the 5% regulatory threshold that would trigger a mandatory public disclosure filing with the U.S. Securities and Exchange Commission.

In its announcement, Kaos Capital stated that BioRestorative Therapies is currently failing to maximize value for its investment base.

The hedge fund believes that initiating a comprehensive strategic review and exploring a structural shift into the artificial intelligence sector represents the most effective path to unlocking dormant shareholder value.

BioRestorative Therapies has historically focused on developing stem cell-based therapies targeting chronic lumbar disc disease and metabolic disorders.

The activist pressure from Kaos Capital reflects a broader trend of institutional investors pushing micro-cap life sciences firms to adopt computational tech strategies to capture market interest and shorten development cycles.

Representatives from Kaos Capital intend to engage with BioRestorative’s management and board of directors to discuss corporate governance, structural alternatives, and options to integrate machine learning and computational applications into the company's broader corporate framework.